There’s no need to worry on the safety or efficacy of the anti-swine flu vaccines being currently developed in different countries, said the World Health Organization.
Taking notice of the fears being expressed in different quarters on the safety or risks in using the vaccines, the WHO said the regulatory procedures in place for the licencing of pandemic vaccines, including procedures for expediting regulatory approval, are rigorous and do not compromise safety or quality.
Drug companies in several countries are in an advanced stage of developing a H1N1 influenza vaccine to check the swine flu pandemic which has swept across over 160 countries, affecting over 1.5 million (confirmed cases; actual number may be far higher) and killing nearly 1,000 persons. In India, too, over two dozen people have lost their lives due to swine flu in recent weeks, in different cities.
Some Indian drug companies are also engaged in developing a swine flu vaccine based on the seed strain of H1N1 influenza virus provided by the WHO. However, it may take a few months to develop and test the vaccines and get approval for their general use.
In a statement issued from Geneva, the WHO has said: “Influenza vaccines have been used for over 60 years and have an established record of safety in all age groups.”
At the same time, it has also cautioned that some adverse events may arise during a pandemic when the vaccine is administered on a massive scale.
“Some adverse events, which may be too rare to show up even in large clinic trials, may become apparent when very large numbers of people receive a pandemic vaccine,” the WHO has said, while maintaining that such cases will be rare.
It has observed that nearly 50 million people had died in the 1918 world-wide influenza pandemic, largely because vaccines had not been developed by then.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
